

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Finer et al.

Attorney Docket No.: CYTO 00991

Application No.: 09/724,778

Examiner: UNASSIGNED

Filed: November 28, 2000

Group: 1614

Title: METHODS AND COMPOSITIONS  
UTILIZING QUINAZOLINONES

1614  
PATENT  
RECEIVED  
JAN 17 2002  
TECH CENTER 1600/2900  
7/1/03

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail to: Commissioner for Patents, Washington, DC 20231 on November 15, 2001.

Signed: \_\_\_\_\_

Laura M. Dean

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.56 AND 1.97(c)

Commissioner for Patents  
Washington, DC 20231

Dear Sir:


The references listed in the attached PTO Form 1449 may be material to examination of the above-identified patent application. Applicants submit the list of these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make these references of official record in this application. The above-identified application is a continuation of prior application U.S. Patent Application No. 09/699,047. This prior application is being relied upon for an earlier filing date under 35 U.S.C. § 120. Because the listed references were either cited by the PTO, or submitted to the PTO in the prior application, under 37 CFR § 1.98(d) Applicants submit that copies need not be provided.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is: (i) filed within three (3) months of the filing date of the above-referenced application, (ii) believed to be filed before the mailing date of a first Office Action on the merits, or (iii) believed to be filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under §1.114. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure


Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 50-1339 (Order No. CYTOP009C1).

Respectfully submitted,  
BEYER WEAVER & THOMAS, LLP



Lauren L. Stevens  
Registration No. 36,691

P.O. Box 778  
Berkeley, CA 94704-0778  
(650)961-8300



COPY OF PAPERS  
ORIGINALLY FILED

<b>Form 1449 (Modified)</b>  <b>Information Disclosure Statement By Applicant</b>  (Use Several Sheets if Necessary)	Atty Docket No. CYTOP009C1 Applicant: Finer et al. Filing Date 11/28/00	Application No. 09/724,778  Group 1614
--	--	--

RECEIVED  
JAN 17 2002  
TECH CENTER 1600/2900

**U.S. Patent Documents**

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub- class	Filing Date

**Foreign Patent or Published Foreign Patent Application**

Examiner Initial	No.	Document No.	Publication Date	Country or Patent Office	Class	Sub- class	Translation	
							Yes	No
	A	EP 0903344A1	Mar 24/99	EPO	C07D	239/90		N/A
	B	WO 01/74344 A2	Oct. 11/00	PCT	A61K	31/00		N/A

**Other Documents**

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
Examiner		Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.